THERAPY DOSSIER · th-411b64b26745

Rubiadin-1-methyl ether, an anthraquinone isolated from plant roots

Nutraceutical · No ChEMBL hit for 'rubiadin' or 'rubiadin-1-methyl ether'. ClinicalTrials.gov searched for rubiadin and for anthraquinone extract interventions: zero records. Confirmed zero human trials by search, not assumed.

Non-drug Suggest a correction

Evidence & regulatory context

Mechanism: No ChEMBL hit for 'rubiadin' or 'rubiadin-1-methyl ether'. ClinicalTrials.gov searched for rubiadin and for anthraquinone extract interventions: zero records. Confirmed zero human trials by search, not assumed.
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31780865 ↗2019Reported benefit

Evidence That the Anti-Inflammatory Effect of Rubiadin-1-methyl Ether Has an Immunomodulatory Context.

MouseEndotoxin/LPSSwissMalen = n = 6 per group in vivo; n = 3 per group for in vitro assay…Oral gavage in vivo; added to culture medium in vitroIn vivo 3, 10 and 30 mg/kg; in vitro 30 micromolar (cytotox…Pre-treatment given 1 h before intranasal LPS instillation in vivo; 0.5 h befor…

Model: LPS-induced acute lung injury: intranasal instillation of lipopolysaccharide 5 mg/kg in 50 microlitres PBS under xylazine/ketamine anaesthesia, with bronchoalveolar lavage fluid collected 12 h later; parallel in vitro model of RAW 264.7 macrophages stimulated with LPS 1 microgram/mL

In vivo, Rubiadin-1-methyl ether reduced total leukocyte counts at 10 and 30 mg/kg (43.6 and 55.3% inhibition) and neutrophil migration (48.1 and 68.8%), reduced exudation at all doses, reduced NOx (46.3 to 60.1%) and MPO activity (41.8 to 54.7%), reduced IL-12p70 and IL-6 at all doses, IFN-gamma a…

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…